Search

Your search keyword '"Varga, Andrea"' showing total 890 results
Start Over Author "Varga, Andrea"
890 results on '"Varga, Andrea"'

2. Assessment of cerebral autoregulatory function and inter-hemispheric blood flow in older adults with internal carotid artery stenosis using transcranial Doppler sonography-based measurement of transient hyperemic response after carotid artery compression

Author

Magyar-Stang, Rita, Pál, Hanga, Csányi, Borbála, Gaál, Anna, Mihály, Zsuzsanna, Czinege, Zsófia, Csipo, Tamas, Ungvari, Zoltan, Sótonyi, Péter, Varga, Andrea, Horváth, Tamás, Bereczki, Dániel, Koller, Akos, and Debreczeni, Róbert

Published
2023
Full Text
View/download PDF

5. Microstructural alterations measured by diffusion tensor imaging following transcatheter aortic valve replacement and their association with cerebral ischemic injury and cognitive function — a prospective study

Author

Varga, Andrea, Gyebnár, Gyula, Suhai, Ferenc Imre, Nagy, Anikó Ilona, Kozák, Lajos Rudolf, Póka, Csenge Ágnes, Turáni, Mirjam Franciska, Borzsák, Sarolta, Apor, Astrid, Bartykowszki, Andrea, Szilveszter, Bálint, Kolossváry, Márton, Maurovich-Horvat, Pál, and Merkely, Béla

Published
2022
Full Text
View/download PDF

6. “Empowering Us”: A community-led survey of real-world perspectives of adults with type 1 diabetes using insulin pumps and continuous glucose monitoring to manage their glucose levels

Author

Read, Meaghan, Henshaw, Kim N., Zaharieva, Dessi P., Brown, Tim C., Varga, Andrea E., Bray, Christine, Cox, Michelle, Goody-Rohdin, Pär-Johan, Hider, Kim, Jelleyman, Paul, Jenkins, Alicia, Jones, Carolyn, Kerr, Peggy, Leach, Rob, Martin, Kim, Oreskovic, Natalie, O'Sullivan, Grant, Rucioch, Jasmin, Sims, Catriona, Smart, Carmel, Speight, Jane, Stanistreet, Jamie, Tippett, Michael, Tivalu, Ioaga, Withers, Tania, and O'Neal, David N.

Published
2023
Full Text
View/download PDF

7. Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy.

Author

Schneeweiss, Andreas, Hess, Dagmar, Joerger, Markus, Varga, Andrea, Moulder, Stacy, Tsimberidou, Apostolia M, Ma, Cynthia, Hurvitz, Sara A, Rentzsch, Christine, Rudolph, Marion, Thiele, Silke, Boix, Oliver, Wilkinson, Gary, Lagkadinou, Eleni, and Ocker, Matthias

Subjects
AKT inhibitor, biomarker, breast cancer, pharmacokinetics, phase 1, Oncology and Carcinogenesis
Abstract

This open-label, phase I first-in-human study (NCT01915576) of BAY 1125976, a highly specific and potent allosteric inhibitor of AKT1/2, aimed to evaluate the safety, pharmacokinetics, and maximum tolerated dose of BAY 1125976 in patients with advanced solid tumors. Oral dose escalation was investigated with a continuous once daily (QD) treatment (21 days/cycle) and a twice daily (BID) schedule. A dose expansion in 28 patients with hormone receptor-positive metastatic breast cancer, including nine patients harboring the AKT1E17K mutation, was performed at the recommended phase 2 dose (R2D) of 60 mg BID. Dose-limiting toxicities (Grades 3-4) were increased in transaminases, γ-glutamyltransferase (γ-GT), and alkaline phosphatase in four patients in both schedules and stomach pain in one patient. Of the 78 patients enrolled, one patient had a partial response, 30 had stable disease, and 38 had progressive disease. The clinical benefit rate was 27.9% among 43 patients treated at the R2D. AKT1E17K mutation status was not associated with tumor response. Genetic analyses revealed additional mutations that could promote tumor cell growth despite the inhibition of AKT1/2. BAY 1125976 was well tolerated and inhibited AKT1/2 signaling but did not lead to radiologic or clinical tumor responses. Thus, the refinement of a selection of biomarkers for AKT inhibitors is needed to improve their monotherapy activity.

Published
2019

12. Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA -Mutated, Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced or Metastatic Breast Cancer.

Author

Jhaveri, Komal L., Accordino, Melissa K., Bedard, Philippe L., Cervantes, Andrés, Gambardella, Valentina, Hamilton, Erika, Italiano, Antoine, Kalinsky, Kevin, Krop, Ian E., Oliveira, Mafalda, Schmid, Peter, Saura, Cristina, Turner, Nicholas C., Varga, Andrea, Cheeti, Sravanthi, Hilz, Stephanie, Hutchinson, Katherine E., Jin, Yanling, Royer-Joo, Stephanie, and Peters, Ubong

Published
2024
Full Text
View/download PDF

13. BRAF Modulates the Interplay Between Cell–Cell and Cell–Extracellular Matrix Adhesions in PECAM-1-Mediated Mechanotransduction.

Author

Gráczer, Éva, Pászty, Katalin, Harsányi, Laura, Lehoczky, Csilla, Fülöp, Antónia, and Varga, Andrea

Subjects
CELL adhesion molecules, YAP signaling proteins, CANCER cell migration, TISSUE adhesions, MECHANOTRANSDUCTION (Cytology)
Abstract

Mechanotransduction, the process of how cells sense and convert mechanical stimuli into biochemical response, is crucial in the migration of leukocytes or cancer cells through the endothelium during inflammation or metastasis. Migrating cells exert forces on the endothelium through cell surface adhesion molecules, such as platelet endothelial adhesion molecule PECAM-1, and this is essential for a successful transmigration. To study PECAM-1-mediated mechanotransduction, we applied PECAM-1-antibody-coated magnetic beads and exerted about 40 pN force on the endothelial monolayer. We show that force increases cell–ECM adhesion in the cell center and is accompanied by the opening of cell–cell junctions. Upon depletion of the MEK/ERK kinase, BRAF force increases cell–ECM adhesion both at the cell periphery and in the cell center, but this does not result in the opening of cell–cell junctions. Decreasing cell–ECM adhesion in BRAF-depleted cells through FAK inhibition results in the remodeling of cell–cell junctions. Force-induced increase in cell–ECM adhesion in the cell center correlates with the activation of the transcriptional cofactor Yes-associated protein (YAP). Furthermore, the induced activation of YAP through LATS inhibition prevents junctional remodeling in control cells. Thus, the activation of YAP might determine the strength of cell–cell junctions during PECAM-1-mediated mechanotransduction. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Pembrolizumab for the Treatment of Advanced Salivary Gland Carcinoma

Author

Cohen, Roger B, Delord, Jean-Pierre, Doi, Toshihiko, Piha-Paul, Sarina A, Liu, Stephen V, Gilbert, Jill, Algazi, Alain P, Damian, Silvia, Hong, Ruey-Long, Le Tourneau, Christophe, Day, Daphne, Varga, Andrea, Elez, Elena, Wallmark, John, Saraf, Sanatan, Thanigaimani, Pradeep, Cheng, Jonathan, and Keam, Bhumsuk

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Research, Cancer, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, salivary gland cancer, immunotherapy, pembrolizumab, anti-PD-1, Dentistry, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

ObjectivesTreatment options for patients with unresectable or metastatic salivary gland carcinoma (SGC) are limited. Safety and efficacy of pembrolizumab for SGC expressing programmed death ligand 1 (PD-L1) were explored.Materials and methodsA cohort of patients with advanced, PD-L1-positive SGC was enrolled in the nonrandomized, multicohort, phase Ib trial of pembrolizumab in patients with PD-L1-positive advanced solid tumors (KEYNOTE-028; NCT02054806). Key inclusion criteria included recurrent or metastatic disease, failure of prior systemic therapy, and PD-L1 expression on ≥1% of tumor or stroma cells (per a prototype immunohistochemistry assay). Patients received pembrolizumab 10 mg/kg every 2 weeks for ≥2 years or until confirmed disease progression or unacceptable toxicity. Primary end point was objective response rate per Response Evaluation Criteria in Solid Tumors version 1.1 by investigator review.ResultsTwenty-six patients with PD-L1-positive SGC were enrolled and treated; median age was 57 years, 88% were men, and 74% had received prior therapy for recurrent/metastatic disease. Confirmed objective response rate after median follow-up of 20 months was 12% (95% confidence interval, 2%-30%), with 3 patients achieving partial response; there were no complete responses. Median duration of response was 4 months (range, 4 to 21 mo). Treatment-related adverse events occurred in 22 patients (85%), resulting in discontinuation in 2 patients and death in 1 (interstitial lung disease); those occurring in ≥15% of patients were diarrhea, decreased appetite, pruritus, and fatigue.ConclusionsPembrolizumab demonstrated promising antitumor activity and a manageable safety profile in patients with advanced, PD-L1-positive SGC.

Published
2018

18. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer

Author

Smyth, Lillian M., Batist, Gerald, Meric-Bernstam, Funda, Kabos, Peter, Spanggaard, Iben, Lluch, Ana, Jhaveri, Komal, Varga, Andrea, Wong, Andrea, Schram, Alison M., Ambrose, Helen, Carr, T. Hedley, de Bruin, Elza C., Salinas-Souza, Carolina, Foxley, Andrew, Hauser, Joana, Lindemann, Justin P. O., Maudsley, Rhiannon, McEwen, Robert, Moschetta, Michele, Nikolaou, Myria, Schiavon, Gaia, Razavi, Pedram, Banerji, Udai, Baselga, José, Hyman, David M., and Chandarlapaty, Sarat

Published
2021
Full Text
View/download PDF

23. Introduction

Author

Retter, Mark, primary, Varga, Andrea, additional, and Weller, Marc, additional

Published
2021
Full Text
View/download PDF

25. Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology

Author

Martin-Romano, Patricia, Mezquita, Laura, Hollebecque, Antoine, Lacroix, Ludovic, Rouleau, Etienne, Gazzah, Anas, Bahleda, Rastilav, Planchard, David, Varga, Andrea, Baldini, Capucine, Postel-Vinay, Sophie, Friboulet, Luc, Loriot, Yohann, Verlingue, Loic, Geraud, Arthur, Camus, Maud Ngo, Nicotra, Claudio, Soria, Jean Charles, André, Fabrice, Besse, Benjamin, Massard, Christophe, and Italiano, Antoine

Published
2022
Full Text
View/download PDF

27. Exploiting domain knowledge for cross-domain text classification in heterogeneous data sources

Author

Varga, Andrea and Ciravegna, Fabio

Subjects
004
Abstract

With the growing amount of data generated in large heterogeneous repositories (such as the Word Wide Web, corporate repositories, citation databases), there is an increased need for the end users to locate relevant information efficiently. Text Classification (TC) techniques provide automated means for classifying fragments of text (phrases, paragraphs or documents) into predefined semantic types, allowing an efficient way for organising and analysing such large document collections. Current approaches to TC rely on supervised learning, which perform well on the domains on which the TC system is built, but tend to adapt poorly to different domains. This thesis presents a body of work for exploring adaptive TC techniques across hetero- geneous corpora in large repositories with the goal of finding novel ways of bridging the gap across domains. The proposed approaches rely on the exploitation of domain knowledge for the derivation of stable cross-domain features. This thesis also investigates novel ways of estimating the performance of a TC classifier, by means of domain similarity measures. For this purpose, two novel knowledge-based similarity measures are proposed that capture the usefulness of the selected cross-domain features for cross-domain TC. The evaluation of these approaches and measures is presented on real world datasets against various strong baseline methods and content-based measures used in transfer learning. This thesis explores how domain knowledge can be used to enhance the representation of documents to address the lexical gap across the domains. Given that the effectiveness of a text classifier largely depends on the availability of annotated data, this thesis explores techniques which can leverage data from social knowledge sources (such as DBpedia and Freebase). Techniques are further presented, which explore the feasibility of exploiting different semantic graph structures from knowledge sources in order to create novel cross- domain features and domain similarity metrics. The methodologies presented provide a novel representation of documents, and exploit four wide coverage knowledge sources: DBpedia, Freebase, SNOMED-CT and MeSH. The contribution of this thesis demonstrates the feasibility of exploiting domain knowl- edge for adaptive TC and domain similarity, providing an enhanced representation of docu- ments with semantic information about entities, that can indeed reduce the lexical differences between domains.

Published
2014

30. Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

Author

Bernard-Tessier, A., Baldini, C., Martin, Patricia, Champiat, Stéphane, Hollebecque, Antoine, Postel-Vinay, Sophie, Varga, Andrea, Bahleda, Rastilav, Gazzah, Anas, Michot, Jean-Marie, Ribrag, Vincent, Armand, Jean-Pierre, Marabelle, Aurélien, Soria, Jean-Charles, and Massard, C.

Published
2018
Full Text
View/download PDF

31. Human epidermal receptor family inhibitors in patients with ERBB3 mutated cancers: Entering the back door

Author

Verlingue, Loic, Hollebecque, Antoine, Lacroix, Ludovic, Postel-Vinay, Sophie, Varga, Andrea, El Dakdouki, Yolla, Baldini, Capucine, Balheda, Rastilav, Gazzah, Anas, Michot, Jean-Marie, Marabelle, Aurélien, Mir, Olivier, Arnedos, Monica, Rouleau, Etienne, Solary, Eric, De Baere, Thierry, Angevin, Eric, Armand, Jean-Pierre, Michiels, Stefan, André, Fabrice, Deutsch, Eric, Scoazec, Jean-Yves, Soria, Jean-Charles, and Massard, Christophe

Published
2018
Full Text
View/download PDF

32. Are phase I trials safe for older patients?

Author

Baldini, Capucine, Le Saux, Olivia, Helissey, Carole, Aspeslagh, Sandrine, Castanon, Eduardo, Varga, Andrea, Gazzah, Anas, Bahleda, Rastilav, Mir, Olivier, Massard, Christophe, Soria, Jean-Charles, and Hollebecque, Antoine

Published
2018
Full Text
View/download PDF

37. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Author

Bigot, Frédéric, Castanon, Eduardo, Baldini, Capucine, Hollebecque, Antoine, Carmona, Alberto, Postel-Vinay, Sophie, Angevin, Eric, Armand, Jean-Pierre, Ribrag, Vincent, Aspeslagh, Sandrine, Varga, Andrea, Bahleda, Rastislav, Menis, Jessica, Gazzah, Anas, Michot, Jean-Marie, Marabelle, Aurélien, Soria, Jean-Charles, and Massard, Christophe

Published
2017
Full Text
View/download PDF

38. Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study

Author

Angevin, Eric, Cassier, Philippe A., Italiano, Antoine, Gonçalves, Anthony, Gazzah, Anas, Terret, Catherine, Toulmonde, Maud, Gravis, Gwenaëlle, Varga, Andrea, Parlavecchio, Cédric, Paci, Angelo, Poinsignon, Vianney, Soria, Jean-Charles, Drubay, Damien, and Hollebecque, Antoine

Published
2017
Full Text
View/download PDF

40. Supplementary Table S4 from Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma

Author

Danlos, François-Xavier, primary, Texier, Matthieu, primary, Job, Bastien, primary, Mouraud, Severine, primary, Cassard, Lydie, primary, Baldini, Capucine, primary, Varga, Andrea, primary, Yurchenko, Andrey A., primary, Rabeau, Audrey, primary, Champiat, Stéphane, primary, Letourneur, Diane, primary, Bredel, Delphine, primary, Susini, Sandrine, primary, Blum, Yuna, primary, Parpaleix, Aurelien, primary, Parlavecchio, Cedric, primary, Tselikas, Lambros, primary, Fahrner, Jean-Eudes, primary, Goubet, Anne-Gaelle, primary, Rouanne, Mathieu, primary, Rafie, Saloomeh, primary, Abbassi, Alae, primary, Kasraoui, Ines, primary, Breckler, Marie, primary, Farhane, Siham, primary, Ammari, Samy, primary, Laghouati, Salim, primary, Gazzah, Anas, primary, Lacroix, Ludovic, primary, Besse, Benjamin, primary, Droin, Nathalie, primary, Deloger, Marc, primary, Cotteret, Sophie, primary, Adam, Julien, primary, Zitvogel, Laurence, primary, Nikolaev, Sergey I., primary, Chaput, Nathalie, primary, Massard, Christophe, primary, Soria, Jean-Charles, primary, Gomez-Roca, Carlos, primary, Zalcman, Gerard, primary, Planchard, David, primary, and Marabelle, Aurelien, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure S5 from Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma

Author

Danlos, François-Xavier, primary, Texier, Matthieu, primary, Job, Bastien, primary, Mouraud, Severine, primary, Cassard, Lydie, primary, Baldini, Capucine, primary, Varga, Andrea, primary, Yurchenko, Andrey A., primary, Rabeau, Audrey, primary, Champiat, Stéphane, primary, Letourneur, Diane, primary, Bredel, Delphine, primary, Susini, Sandrine, primary, Blum, Yuna, primary, Parpaleix, Aurelien, primary, Parlavecchio, Cedric, primary, Tselikas, Lambros, primary, Fahrner, Jean-Eudes, primary, Goubet, Anne-Gaelle, primary, Rouanne, Mathieu, primary, Rafie, Saloomeh, primary, Abbassi, Alae, primary, Kasraoui, Ines, primary, Breckler, Marie, primary, Farhane, Siham, primary, Ammari, Samy, primary, Laghouati, Salim, primary, Gazzah, Anas, primary, Lacroix, Ludovic, primary, Besse, Benjamin, primary, Droin, Nathalie, primary, Deloger, Marc, primary, Cotteret, Sophie, primary, Adam, Julien, primary, Zitvogel, Laurence, primary, Nikolaev, Sergey I., primary, Chaput, Nathalie, primary, Massard, Christophe, primary, Soria, Jean-Charles, primary, Gomez-Roca, Carlos, primary, Zalcman, Gerard, primary, Planchard, David, primary, and Marabelle, Aurelien, primary

Published
2023
Full Text
View/download PDF

42. Data from Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti–PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma

Author

Danlos, François-Xavier, primary, Texier, Matthieu, primary, Job, Bastien, primary, Mouraud, Severine, primary, Cassard, Lydie, primary, Baldini, Capucine, primary, Varga, Andrea, primary, Yurchenko, Andrey A., primary, Rabeau, Audrey, primary, Champiat, Stéphane, primary, Letourneur, Diane, primary, Bredel, Delphine, primary, Susini, Sandrine, primary, Blum, Yuna, primary, Parpaleix, Aurelien, primary, Parlavecchio, Cedric, primary, Tselikas, Lambros, primary, Fahrner, Jean-Eudes, primary, Goubet, Anne-Gaelle, primary, Rouanne, Mathieu, primary, Rafie, Saloomeh, primary, Abbassi, Alae, primary, Kasraoui, Ines, primary, Breckler, Marie, primary, Farhane, Siham, primary, Ammari, Samy, primary, Laghouati, Salim, primary, Gazzah, Anas, primary, Lacroix, Ludovic, primary, Besse, Benjamin, primary, Droin, Nathalie, primary, Deloger, Marc, primary, Cotteret, Sophie, primary, Adam, Julien, primary, Zitvogel, Laurence, primary, Nikolaev, Sergey I., primary, Chaput, Nathalie, primary, Massard, Christophe, primary, Soria, Jean-Charles, primary, Gomez-Roca, Carlos, primary, Zalcman, Gerard, primary, Planchard, David, primary, and Marabelle, Aurelien, primary

Published
2023
Full Text
View/download PDF

43. Supplementary Methods from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

44. Data from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

45. Supplementary Figure Legends from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

46. Supplementary Figure 1 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

47. Supplementary Figure 2 from High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial

Author

Massard, Christophe, primary, Michiels, Stefan, primary, Ferté, Charles, primary, Le Deley, Marie-Cécile, primary, Lacroix, Ludovic, primary, Hollebecque, Antoine, primary, Verlingue, Loic, primary, Ileana, Ecaterina, primary, Rosellini, Silvia, primary, Ammari, Samy, primary, Ngo-Camus, Maud, primary, Bahleda, Rastislav, primary, Gazzah, Anas, primary, Varga, Andrea, primary, Postel-Vinay, Sophie, primary, Loriot, Yohann, primary, Even, Caroline, primary, Breuskin, Ingrid, primary, Auger, Nathalie, primary, Job, Bastien, primary, De Baere, Thierry, primary, Deschamps, Frederic, primary, Vielh, Philippe, primary, Scoazec, Jean-Yves, primary, Lazar, Vladimir, primary, Richon, Catherine, primary, Ribrag, Vincent, primary, Deutsch, Eric, primary, Angevin, Eric, primary, Vassal, Gilles, primary, Eggermont, Alexander, primary, André, Fabrice, primary, and Soria, Jean-Charles, primary

Published
2023
Full Text
View/download PDF

48. Supplementary Data from Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation

Author

Gauci, Marie-Léa, primary, Lanoy, Emilie, primary, Champiat, Stéphane, primary, Caramella, Caroline, primary, Ammari, Samy, primary, Aspeslagh, Sandrine, primary, Varga, Andrea, primary, Baldini, Capucine, primary, Bahleda, Rastilav, primary, Gazzah, Anas, primary, Michot, Jean-Marie, primary, Postel-Vinay, Sophie, primary, Angevin, Eric, primary, Ribrag, Vincent, primary, Hollebecque, Antoine, primary, Soria, Jean-Charles, primary, Robert, Caroline, primary, Massard, Christophe, primary, and Marabelle, Aurélien, primary

Published
2023
Full Text
View/download PDF

49. Supplementary Figure 2 from A First-in-Human Phase I Study to Evaluate the ERK1/2 Inhibitor GDC-0994 in Patients with Advanced Solid Tumors

Author

Varga, Andrea, primary, Soria, Jean-Charles, primary, Hollebecque, Antoine, primary, LoRusso, Patricia, primary, Bendell, Johanna, primary, Huang, Shih-Min A., primary, Wagle, Marie-Claire, primary, Okrah, Kwame, primary, Liu, Lichuan, primary, Murray, Elaine, primary, Sanabria-Bohorquez, Sandra M., primary, Tagen, Michael, primary, Dokainish, Hatem, primary, Mueller, Lars, primary, and Burris, Howard, primary

Published
2023
Full Text
View/download PDF

50. Supplementary Tables 1 - 2, Figure 1 from A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Author

Ribrag, Vincent, primary, Dupuis, Jehan, primary, Tilly, Herve, primary, Morschhauser, Franck, primary, Laine, Fabrice, primary, Houot, Roch, primary, Haioun, Corinne, primary, Copie, Christiane, primary, Varga, Andrea, primary, Lambert, John, primary, Hatteville, Laurence, primary, Ziti-Ljajic, Samira, primary, Caron, Anne, primary, Payrard, Sandrine, primary, and Coiffier, Bertrand, primary

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results